Notícias Corporativas

The all-staff meeting at the beginning of each year is a special time to bring the entire FarmaMondo family together virtually. Colleagues from every part of the Group—Latin America, Asia, the Middle East, Europe, and the head office in Switzerland—connect with one another.

FarmaMondo Hong Kong Limited  confirms the approval of the reimbursement for Carbaglu (Carglumic Acid) dispersible tablets, on behalf of Recordati Rare Diseases in Hong Kong.

FarmaMondo at the annual congress of the GSASA (Swiss Association of Hospital Pharmacists)

Breast Cancer Seminar November 21, 6.30 pm – We are pleased to invite you to the Hybrid Seminar on the Therapeutic updates for Breast Cancer.

The BIO Europe conference in Stockholm brings together key players in the biotech scene and therapeutic innovation well beyond Europe. Evgeny Pashanov, Global Medical Director,

The FarmaMondo Group’s Executive team convened last week for its regular cycle meeting. The Executive team includes regional managing directors, who lead the Group’s commercial

Farma Mondo announces the signing with Recordati UK Ltd. (a Recordati Rare Diseases Company) of an exclusive License and Distribution Agreement in Hong Kong for Qarziba® (dinutuximab beta)

CHIASSO, Switzerland and Châtillon, France – June 21, 2024 – Farma Mondo Group, a Swiss-based pharmaceutical company, and HRA Pharma Rare Diseases, are pleased to announce the signing of an Exclusive Distribution Agreement for the supply of Lysodren (Mitotane) in Brazil.

FarmaMondo fosters a culture of innovation and optimization. For this reason, it recognizes annual merit Awards to employees who have distinguished themselves in commitment and

FarmaMondo’s Uruguay office and regional logistics centre is the last major step in expanding our footprint.
After several months of intensive preparations, with the visit of the CFO Giuseppe Malanga and the Latam management Daniel Tanana (Managing Director) and Horacio Rosendo (Finance & Operations Director), the new hub has been kicked off and now it is fully operational.

Farma Mondo Group and Stemline Therapeutics B.V. sign exclusive partnership to grant access to Elacestrant through Named Patient Supplies to patients in certain Countries where the product is not licensed or not commercially available.

FarmaMondo took part in Arab Health 2024 in Dubai at the end of January. Arab Health is the largest gathering of healthcare industry professionals in

Farmamondo’s Supply Chain Team (part of the Extended Supply Chain team) is proud to announce the full effective availability of our second new Cold Room in FarmaMondo’s Central

While FarmaMondo is a decentralised organisation very close to our customers, our amazing Finance and Information Technology team is supporting the business from Switzerland Headquarter, guaranteeing a solid financial sustainability.

Our Customer Service and Operational Excellence is not just a department; it’s a commitment! We embrace values of reliability, affordability and sustainability to address your

Le congrès de la GSASA commence dans 2 semaines ! Der GSASA-Kongress beginnt in zwei Wochen! FarmaMondo has been supporting GSASA for many years et our

Quality and Compliance are at the center of our added value and expertise offered to our industry partners from the 14 affiliates of the FarmaMondo

FarmaMondo will be participating in the Bio-Europe Congress in Munich from 6 to 8 November. BIO-Europe® is held annually in different cities and is an

MILAN, ITALY and CHIASSO, SWITZERLAND, June 1, 2023 – Dompé farmaceutici S.p.A. (“Dompé”) and FarmaMondo Group announced they have extended their agreement whereby FarmaMondo Group becomes Dompé’s distribution partner for Oxervate (cenegermin) in additional selected countries. 

Chiasso, Switzerland and Ashburn, US – 28th July, 2023 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, announces today the signing of a licensing and distribution agreement with Quoin Pharmaceuticals Inc. for exclusive rights to commercialize QRX003 in Singapore.

Receiving awards from a business partner is an amazing sign of recognition. Even more so when you double down! Two FarmaMondo affiliates were honoured last

A wonderful family photo of the FarmaMondo Swiss team, bigger than ever, in front of our headquarters in Chiasso, Switzerland. The growth of the team underlines the

Visit of Yaron Spigel, CEO of the FarmaMondo Group to our APAC leadership team in Hong Kong. Between sessions and deep business and medical discussions,

Bottom-up decisions are excellent. The FarmaMondo team has decided to dedicate one day a month to “Healthy Nutrition Day”. It could be every day, but

We are delighted to be rolling out our recently upgraded compliance programme globally. In April, all Global FarmaMondo teams participated in a compliance training across

How to bring innovative therapies to patients in growth and emerging markets is a real challenge for medium and small biotechnology companies. FarmaMondo has a

Homozygous Familial Hypercholesterolemia (HoFH) is a rare life-threatening genetic disorder characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) in the blood and premature

Our activities in the APAC region are expanding and, to support our growth, the team has been complemented not only by highly qualified experts, such

Shortages and reliability of drug supply were high on the agenda of most participants of the European Association of Hospital Pharmacists Congress. As a world

FarmaMondo’s extended supply chain serves patients and healthcare professionals in 80 countries. To maintain the highest quality standards, we are constantly adapting to the changing

Come visit us at our booth in the EAHP Congress in Lisbon. From the 22th to the 24th March FarmaMondo will attend the 2023 European

FarmaMondo and Kyan Technologies sign an exclusive marketing and distribution agreement in the MENA region for its OPTIM.AI platform, a revolutionary phenotypic response technology highly efficient in identifying safe and effective ​drug-dose combinations based on small inputs of data.

The testimonies of the families are a gift that underlines our mission. After his bone marrow transplant, young Enzo in Argentina was finally able to

First business review of the year in Portugal with our team and distribution partners. Thank you to all, especially Joao and Alexandra, for the intense

Happy Season’s greetings from our team to yours!  

We are delighted to announce that the FarmaMondo Group and Helsinn Group have entered an exclusive marketing and distribution agreement for the treatment in adults

FarmaMondo and Helsinn sign an exclusive marketing and distribution agreement in the Baltic region for AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults.

Key note intervention of Nicolas Moretti, FarmaMondo Managing Director, on the topic “Boosting Patient Reach and Product Value” at World Orphan Drug Congress Europe in Sitges, Spain.

The FarmaMondo team is ready to welcome you to our booth. We look forward to meeting the patient organisations, innovative biotech companies and key stakeholders

Incredible strategy workshop for the global FarmaMondo leadership team in Serpiano, Switzerland. We were blessed with beautiful weather that gave us a breath-taking view of Lake Lugano.

We are very happy to have given an “Award For Excellence” to Isabelle Losa-Lin this week. It is a sign of recognition for her extraordinary

Recordati Rare Diseases appoints the FarmaMondo Group as the exclusive commercial partner for its orphan therapies Cosmegen®, Pedea® and Carbaglu® in Hong Kong. Under the

Are you planning to visit the CPHI in Frankfurt? CPHI is the leading trade fair for the pharmaceutical sector. The next edition of the expo

FarmaMondo Group CEO, Yaron Spigel, visited our Singapore office for a business review. After two years of virtual meetings due to the COVID restrictions, finally

FarmaMondo @Expopharm in Munich The FarmaMondo’s team took part in the Expopharm congress last week in Munich. After dozens of incredible meetings with our trusted

Qarziba® is an anti-GD2 monoclonal antibody that has shown to improve significantly the event-free and overall survival in children with high-risk neuroblastoma, with an acceptable safety profile.

FarmaMondo represents an innovative worldwide drug for the treatment of advanced neuroblastoma and is proud to announce its distribution also in Chile.

Molteni Farmaceutici and the FarmaMondo Group signed an exclusive marketing and distribution agreement for certain Molteni’s products of its pain and addiction management portfolio in

Amryt Pharma and the FarmaMondo Group signed an exclusive partnership agreement for the orphan disease innovative therapies Myalept®, Lojuxta® in the APAC region.

The Forset Hayat Foundation, the Egyptian charitable organisation supporting children with rare diseases and their families was kick-off in May 2022.

FarmaMondo would like to express its gratitude to this extraordinary group of people.

FarmaMondo has extended The CEO AWARD 2021 to two collaborators for their outstanding performance in the past year.

Come visit us at EAHP in Vienna. From the 23th to the 25th March FarmaMondo will be exhibiting at EAHP (European Hospital pharmacists) in Vienna.

Today is the day dedicated to the more than 300 million people living with rare diseases worldwide. We are proud to play our part in this movement!

FarmaMondo and Accendatech USA Inc. partnered to initiate a Managed Access Program for the compassionate supply of ACT-001 for patients in Hong Kong. Under the

FarmaMondo wishes all our colleagues, clients and patients a Happy Chinese New Year! 2022 is the Year of the Tiger. May the Year of the

FarmaMondo participates in the Arab Health conference in Dubai from 24-27 January 2022. After a break of 2 years, FarmaMondo is delighted to be physically

FarmaMondo has recently the pleasure and honor to meet our presumably oldest known client. The two sisters (on the picture) are co-owners of Farmacia Rex

At FarmaMondo, we promote health and remind all women who work with us and those we love of the importance of prevention. Our thoughts are

September 17, 2021 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, today announces that it has signed a license agreement with the Swiss-based FarmaMondo

Mirum Pharmaceuticals (NASDAQ: MIRM) and FarmaMondo entered into an exclusive distribution and supply agreement appointing the FarmaMondo Group as the exclusive partner to make their

Ideogen AG and FarmaMondo enter into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner for their innovative PTCL

The FarmaMondo Group announces the establishment of FarmaMondo Pte, a fully owned subsidiary in Singapore. FarmaMondo Pte Singapore will further serve the Group’s development strategy

February 2021 FarmaMondo SA announces the establishment of FarmaMondo Iberia, in Portugal, a fully owned subsidiary of FarmaMondo SA. The Iberian Subsidiary will further enhance

December 2020 – FarmaMondo SA announced an exclusive distribution of eteplirsen and golodirsen for certain patients with Duchenne muscular dystrophy (DMD) in Russia. FarmaMondo SA,

November 2020 – Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner

FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce

FarmaMondo and Zion Medical, an Israel startup pharma developer, signed today an agreement to establish a MAP for their novel drug Gammora. The product is

Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Metreleptin (FDA/EMA approval under

While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO trial – https://clinicaltrials.gov/ct2/show/NCT04322188?term=SISCO&draw=2&rank=1)  on Siltuximab

Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Lomitapide (EMA

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines has been appointed by EUSA Pharma to extend its current exclusive distribution of Qarziba®

FarmaMondo has been appointed to exclusively manage the access of Carmustine Obvius to Italian healthcare providers looking to fulfill unmet medical needs of patients with

FarmaMondo SA announces it has established FarmaMondo Mexico, a fully owned subsidiary of FarmaMondo SA. The Mexican affiliate will upgrade the group’s capabilities in providing

FarmaMondo Nordics Aps, a fully owned subsidiary of FarmaMondo SA, has received a GMP license from the Danish Medicines Agency. With this license in place,

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in

Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung cancer in a trial whose results

AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR)

FarmaMondo Team is pleased to inform you that  is attending Pharmagora Paris 2018. PharmagoraPlus has been the single largest conference and exhibition in France dedicated to

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin® via a Managed Access

Read the full interview, appeared on the magazine Healthcare and Life Sciences Review with our CEO, Mr. Yaron Spigel, regarding the uniqueness of FarmaMondo business

FarmaMondo SA announces it has established operations through its Global Access business unit into several south EU markets to allow direct to hospital supply of

FarmaMondo Team is pleased to inform you that also for 2018 is attending Arab Health in Dubai. Arab Health is the largest gathering of healthcare

FarmaMondo has recently hosted two days of medical workshops in Saint Petersburg and Moscow on November 9th and 10th 2017, as part of its support for

FarmaMondo SA announces it has established operations in Mexico to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and our portfolio

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by EUSA Pharma to exclusively distribute Qarziba® via a Managed Access

Following the successful and great experience of last 2 years’ participation FarmaMondo will return again to exhibit at EXPOPHARM 2017which will be held in Düsseldorf,

FarmaMondo is delighted to announce further expansion of its Russian operations. As of July 1st 2017 FarmaMondo Representative Office (Moscow, Russia) provides full service coverage

Following the successful experience of last year’s participation FarmaMondo will return to exhibit at EXPOPHARM 2016 which will be held in Munich, Germany from October

FarmaMondo is proud to sponsor this unique event, Early Access Programmes Conference, held in London , UK, on 29th – 30 th November 2016. The

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Ideogen Pharma to exclusively distribute Bicnu® (Emcure) via a Managed

Farmamondo and AOP Orphan signs an exclusive registration, marketing and distribution agreement for AOP’s novel therapy Tetrabenazine indicated for Huntington disease. The agreement covers the

FarmaMondo approves Normokineztine in Russian Federation for Huntington disease patients. The product, license to FarmaMondo from AOP Orphan, has been approved as the sole indicated

FarmaMondo announces the approval of Ellanse, an innovative product in the esthetic segment, by the Taiwan local regulatory body – TFDA – as a medical

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed to exclusively distribute Curefini® dermal ointment via a Managed Access Program

FarmaMondo is proud to announce that has been honored as “One of the Top trustworthy Swiss companies” by Dun & Bradstreet, a considerable business information

FarmaMondo completes a rebranding campaign for its Swiss local retail unit. The Swiss retail unit, known to be the corner stone of the FarmaMondo historical

FarmaMondo SA announces it has established operations in Argentina to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and in support

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Orion Pharma to distribute Simdax® via a Managed Access Program

FarmaMondo announces the establishment of its Brazilian subsidiary in Sao Paolo, Brazil. The subsidiary will facilitate the company’s vision and strategies in the Brazilian market

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by ADIENNE to distribute Tepadina® via a Managed Access Program for

FarmaMondo SA announces it has established operations in Beijing, China. The Chinese affiliate will upgrade the FarmaMondo group capabilities in providing paid access to unlicensed